The Effect of Melatonin in Patients With Low Anterior Resection Syndrome

Low Anterior Resection Syndrome Clinical Trial

— MELLARS  

Official title:

The Effect of Melatonin in Patients With Low Anterior Resection Syndrome

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05042700
• Other study ID #: REG-140-2020
• Secondary ID: 2020-004442-11
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 13, 2021
• Est. completion date: December 2023

Study information

• Verified date: April 2023
• Source: Zealand University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to investigate whether treatment with melatonin has an alleviating effect on Low Anterior Resection Syndrome (LARS) symptoms. Secondarily, the effect of the treatment on bowel movements, other patient reported symptoms, quality of life, depression, anxiety, sleep disturbances, motilin levels, and microscopic changes in rectal mucosa will be investigated.

Description:

This trial which will be conducted in two phases.

The first part of the study will be conducted as an internal feasibility test. Three patients with major LARS will be included. Patients will be recruited from the Department of Surgery, Zealand University Hospital. These patients will not be randomized nor blinded. They will receive a 4-week treatment with 25 mg melatonin and will undergo the same questionnaires and tests before and after treatment as in the randomized clinical trial. The preliminary results from the internal feasibility test will allow us to assess potential difficulties related to the administration or design, which then will be able to be corrected before the randomization part is initiated.

The second part of the will be conducted as a randomized, blinded, placebo-controlled, crossover study and will be testing whether treatment with melatonin has an alleviating effect on Low Anterior Resection Syndrome (LARS) symptoms.

Patients will be randomized to receive 4 weeks of treatment with melatonin, followed by a 4 week wash out period, and then 4 weeks of treatment with placebo (M-P) or 4 weeks of treatment with placebo, followed by a 4 week wash out period, and then 4 weeks of treatment with melatonin (P-M). Both participants and investigators will be blinded.

Patients will be given questionnaires before and after each treatment period to assess outcomes. Blood samples and rectal biopsies will be taken after each treatment period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients should have major LARS (LARS score >29).

2. Patients should have undergone bowel continuity restoring surgery between the last 3 to 24 months.

3. Participants should be 18 years or older.

4. Participants must sign an informed consent form.

Exclusion Criteria:

1. Known allergic reaction to melatonin.

2. Dementia as determined by mini mental state examination score (MMSE) < 24.

3. Participation in another pharmacological intervention trial at the point of inclusion.

4. Completed any adjuvant oncological treatment within the last three months.

5. Ongoing oncological treatment.

6. Rotor or Dubin-Johnson syndrome, epilepsy, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Parkinson's disease, spinal cord injury and multiple sclerosis.

7. Severe liver disease defined as transaminases above 3 times the normal levels, and severe kidney disease defined as eGFR below 40 ml/min.

8. Daily ongoing hypnotic treatment.

9. Pre-existing medical sleep disorder diagnosed before the diagnosis of rectal cancer (i.e sleep apnea, restless legs, narcolepsy.)

10. Work involving nightshifts.

11. Daily alcohol consumption above 5 units of alcohol (1 unit = 12 g alcohol)

12. Predictable poor compliance (due to pre-existing psychiatric disease, dementia or not able to read or speak sufficient Danish)

13. Pregnant or breastfeeding.

14. Severe, life-threatening medical condition, that implies that the patient cannot participate in the study course. (e.g. metastatic disease, local recurrence, stroke, AMI).

15. Females not in menopause (defined as no menstruation during the last 12 months) should not be pregnant. Furthermore, reproductive females should use a secure birth control (intrauterine devices, hormonal contraceptives including - oral pills, patches, vaginal rings and injections) during the entire period of the trial.

Related Conditions & MeSH terms

• Low Anterior Resection Syndrome
• Syndrome

Intervention

Drug:
• Melatonin
Enema with 25 mg melatonin
• Placebo
Enema without melatonin

Locations

Country	Name	City	State
Denmark	Zealand University Hospital	Køge	Region Sjælland

Sponsors (3)

Lead Sponsor	Collaborator
Ismail Gögenur	Aarhus University Hospital, Hvidovre University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Low Anterior Resection Syndrome Score	The LARS Score questionnaire is filled out by the participants before and after each treatment period.	4 weeks
Secondary	Daily bowel function	The participants will fill out a diary on the daily bowel movements during the treatment phase	4 weeks
Secondary	Self-reported quality of life	EORTC Quality of Life Questionnaire for cancer patients and specifically colorectal cancer patients	4 weeks
Secondary	Other patient reported symptoms	Measure Yourself Medical Outcome Profile (MYMOP) is a self-administered questionnaire. Patients are asked to specify one or two symptoms that concern them the most. Subsequently they evaluate the severity on a 7-point Likert scale. The second part of the questionnaire uses the same scale to assess whether the symptom limits or prevent any daily activity, and also to rate general well-being. Follow-up questionnaires address the original issues completed in the initial form. Symptom 1, symptom 2, activity, and wellbeing each have a separate score between 0 and 6 with 0 indicating "as good as it could be" and 6 "as bad as it could be". An overall score is calculated by taking the average of item scores.	4 weeks
Secondary	Anxiety	Hospital Anxiety and Depression Scale (HADS-A): The anxiety subscale consists of 7 questions which are graded on a 4 point scale (0-1-2-3) and is summed into a total score between 0-21. A score of 7 or lower is negative case, a score of 8 - 10 is a doubtful case, and a score of 11 or above is a positive case.	4 weeks
Secondary	Depression	Hospital Anxiety and Depression Scale (HADS-D): The depression subscale consists of 7 questions which are graded on a 4 point scale (0-1-2-3) and is summed into a total score between 0-21. A score of 7 or lower is negative case, a score of 8 - 10 is a doubtful case, and a score of 11 or above is a positive case.	4 weeks
Secondary	Sleep	Participants will wear an actigraph during the treatment phases and fill out a sleep diary and this will allow to asses sleep time (minutes).	4 weeks
Secondary	Insomnia	Insomnia Severity Index (ISI)	4 weeks
Secondary	Incidence of treatment-emergent Adverse Effects [Safety and reactions]	Participants will be systematically interviewed before and after the treatment periods.	4 weeks
Secondary	Melatonin	Blood samples will be taken after each treatment ends.	4 weeks
Secondary	Multiplex gene assay - NanoString nCounter® Inflammation Panel analysis in blood	Difference in gene expressions between intervention and placebo groups	4 weeks
Secondary	Motilin	Blood samples will be taken after each treatment ends.	4 weeks
Secondary	Pathological assessment of inflammation	Rectal biopsies will be taken after each treatment ends.The FFPE treated biopsies will be assessed by pathologist using a routine inflammatory grading system to asses inflammation	4 weeks
Secondary	Multiplex gene assay - NanoString nCounter® Inflammation Panel analysis in biopsies	Difference in gene expressions between intervention and placebo groups	4 weeks
Secondary	Motilin receptors	Rectal biopsies will be taken after each treatment ends.	4 weeks